<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00893555</url>
  </required_header>
  <id_info>
    <org_study_id>VORI911</org_study_id>
    <nct_id>NCT00893555</nct_id>
  </id_info>
  <brief_title>Pharmacologic Optimization of Voriconazole</brief_title>
  <acronym>VORI911</acronym>
  <official_title>Pharmacologic Optimization of Voriconazole - a Prospective Clustered Group-randomized Cross-over Trial of Therapeutic Drug Monitoring</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jan-Willem C Alffenaar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Medical Center Nijmegen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Antonius Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Meander Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Haga Hospital, Leyweg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Klinikum Oldenburg gGmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study proposal is to determine whether pharmacologic optimization of
      voriconazole by means of therapeutic drug monitoring (TDM) results in improved patient
      outcomes (efficacy and safety) and is more cost-effective compared to the current standard of
      care.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with haematological malignancies and chemotherapy-induced prolonged neutropenia are
      at risk for severe bacterial and fungal infections. These opportunistic infections can result
      in prolonged hospital stay, increases costs and greater mortality. Voriconazole has now been
      recommended as the first line agent for invasive pulmonary aspergillosis. Retrospective
      observational studies of voriconazole serum concentration suggest that serum concentration
      correlate with toxicity and clinical response. These observations were however made in small
      series of patients and data were collected retrospectively. These inherent methodological
      flaws make it impossible to draw definite conclusions about the effect of voriconazole serum
      level monitoring on the outcome of IA, and therefore considered insufficient proof to
      recommend voriconazole concentration determination in blood as standard of care. The impact
      that so called serum concentration guided dosing of voriconazole will have on treatment
      success can only be evaluated through a prospective randomized clinical trial.

      For this purpose, we designed a prospective stratified cluster randomized cross-over trial of
      therapeutic drug monitoring in patients with haematological disease who have developed IA.
      The order of periods (TDM or standard of care, each 12 months) will be randomized per centre.
      During the TDM episode, the voriconazole dosage will be adjusted to achieve trough blood
      concentrations in a predefined window of 2-5 mg/L. A sample size of n=192 is needed to detect
      a 20% absolute reduction in the number of treatment failures (40% to 20 %) compared to
      control.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary clinical endpoint will be a global response consisting of a combined endpoint of toxicity and response to therapy (clinical, microbiologic and radiologic responses) 28 days after starting treatment with voriconazole.</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall mortality</measure>
    <time_frame>7 and 28 days; 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% of serum concentrations within 2-5mg/L</measure>
    <time_frame>7 and 28 days; 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% switched to salvage therapy or measured concentration level in control arm</measure>
    <time_frame>7 and 28 days; 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>7 and 28 days; 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to global response</measure>
    <time_frame>7 and 28 days; 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness of TDM</measure>
    <time_frame>7 and 28 days; 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">189</enrollment>
  <condition>Invasive Fungal Infection</condition>
  <condition>Hematological Malignancy</condition>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Voriconazole dosing based on SPC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TDM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Voriconazole serum concentration based dosing</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>voriconazole</intervention_name>
    <description>TDM (through level of 2-5mg/L).</description>
    <arm_group_label>TDM</arm_group_label>
    <other_name>Vfend</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>voriconazole (dosing according to the SPC)</intervention_name>
    <description>No serum concentrations are determined</description>
    <arm_group_label>control</arm_group_label>
    <other_name>Vfend</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  are at least 18 years of age

          -  have received chemotherapy for haematological malignancies or have received a
             hematopoietic stem cell transplant

          -  proven, probable or possible invasive fungal disease according to the EORTC/MSG
             criteria

          -  treatment with voriconazole

        Exclusion Criteria:

          -  allergic to voriconazole or its excipients

          -  age below 18 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J GW Kosterink, PharmD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>J WC Alffenaar, PharmD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2009</study_first_submitted>
  <study_first_submitted_qc>May 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2009</study_first_posted>
  <last_update_submitted>January 11, 2017</last_update_submitted>
  <last_update_submitted_qc>January 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>Jan-Willem C Alffenaar</investigator_full_name>
    <investigator_title>PhD PharmD</investigator_title>
  </responsible_party>
  <keyword>Invasive fungal infection</keyword>
  <keyword>hematological malignancy</keyword>
  <keyword>voriconazole</keyword>
  <keyword>therapeutic drug monitoring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Invasive Fungal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Voriconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

